[CNAT] Conatus Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.43 Change: 0.66 (17.51%)
Ext. hours: 4.43 Change: 0 (0%)

chart CNAT

Refresh chart

Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-71.33% ROE-82.04% ROI
Current Ratio10.09 Quick Ratio Long Term Debt/Equity0.04 Debt Ratio0.11
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-30 K Cash From Investing Activities4.37 M Cash From Operating Activities-5.95 M Gross Profit
Net Profit-5.98 M Operating Profit-5.96 M Total Assets32.32 M Total Current Assets31.54 M
Total Current Liabilities3.13 M Total Debt1000 K Total Liabilities4.22 M Total Revenue
Technical Data
High 52 week7.5 Low 52 week3.3 Last close3.99 Last change-1.48%
RSI25.76 Average true range0.23 Beta1.35 Volume6.13 M
Simple moving average 20 days-8.38% Simple moving average 50 days-10.25% Simple moving average 200 days-14.59%
Performance Data
Performance Week-4.09% Performance Month-12.69% Performance Quart8.42% Performance Half-28.24%
Performance Year-25.97% Performance Year-to-date-13.64% Volatility daily2.66% Volatility weekly5.95%
Volatility monthly12.2% Volatility yearly42.25% Relative Volume56874.5% Average Volume524.58 K
New High New Low

News

2019-05-24 09:39:55 | How Many Conatus Pharmaceuticals Inc. NASDAQ:CNAT Shares Do Institutions Own?

2019-05-06 14:53:06 | Conatus' CNAT Earnings, Revenues Miss Estimates in Q1

2019-05-02 19:15:11 | Conatus Pharmaceuticals CNAT Reports Q1 Loss, Lags Revenue Estimates

2019-05-02 18:11:35 | Conatus: 1Q Earnings Snapshot

2019-04-30 07:30:00 | Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

2019-04-24 10:33:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-15 07:30:00 | Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

2019-04-07 09:30:01 | Why Is Conatus CNAT Down 37.8% Since Last Earnings Report?

2019-04-02 07:30:00 | Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

2019-03-22 17:43:09 | Conatus CNAT Declines on Failure of NASH Fibrosis Study

2019-03-22 10:49:15 | Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

2019-03-21 16:05:00 | Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

2019-03-20 11:10:03 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan

2019-03-13 10:35:02 | Implied Volatility Surging for Conatus CNAT Stock Options

2019-03-13 09:00:00 | Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

2019-03-11 10:57:02 | Conatus' CNAT Q4 Earnings Top Estimates, Emricasan in Focus

2019-03-08 20:24:59 | Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT

2019-03-08 16:05:00 | Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates

2019-03-01 07:30:00 | Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

2019-02-25 13:20:41 | Is Conatus Pharmaceuticals Inc.’s NASDAQ:CNAT CEO Pay Justified?

2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study

2019-02-12 07:30:00 | Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

2019-01-30 08:05:00 | Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals

2019-01-29 10:05:03 | Can GW Pharmaceuticals GWPH Deliver a Beat in Q1 Earnings?

2019-01-28 07:30:00 | Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

2018-12-28 17:40:10 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan

2018-12-13 09:26:02 | The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

2018-12-12 10:03:03 | Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

2018-12-07 08:04:52 | The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

2018-12-06 14:51:07 | Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

2018-12-06 14:13:00 | Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint

2018-12-06 07:00:00 | Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis

2018-12-05 07:30:00 | Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

2018-11-16 10:42:47 | When Will Conatus Pharmaceuticals Inc NASDAQ:CNAT Become Profitable?

2018-11-16 07:50:00 | Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

2018-11-14 08:46:01 | Do Options Traders Know Something About Conatus CNAT Stock We Don't?

2018-11-08 07:30:00 | Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting

2018-11-02 12:30:04 | Conatus' CNAT Q3 Loss In Line, Revenues Lag Estimates

2018-11-02 12:13:05 | Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT

2018-11-02 07:30:11 | Conatus Pharmaceuticals CNAT Reports Q3 Loss, Misses Revenue Estimates

2018-11-02 05:03:24 | Conatus: 3Q Earnings Snapshot

2018-11-01 16:05:00 | Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

2018-10-25 07:30:00 | Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results

2018-10-22 08:00:00 | Today’s Research Reports on Stocks to Watch: Planet Green and The9 Limited

2018-10-11 08:51:12 | Options Traders Expect Huge Moves in Conatus Pharmaceuticals CNAT Stock

2018-10-02 16:05:00 | Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

2018-09-25 08:00:00 | Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target

2018-09-20 07:30:00 | Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension